Home Cart Sign in  
Chemical Structure| 852391-15-2 Chemical Structure| 852391-15-2

Structure of Necrostatin 2 racemate
CAS No.: 852391-15-2

Chemical Structure| 852391-15-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Necrostatin 2 is a potent necroptosis inhibitor with EC50 of 50 nM.

Synonyms: Nec-1S; Necrostatin 1S; (±)-Necrostatin-2

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Necrostatin 2 racemate

CAS No. :852391-15-2
Formula : C13H12ClN3O2
M.W : 277.71
SMILES Code : O=C1N(C)C(C(CC2=CNC3=C2C=CC=C3Cl)N1)=O
Synonyms :
Nec-1S; Necrostatin 1S; (±)-Necrostatin-2
MDL No. :MFCD26743828
InChI Key :WIKGAEMMNQTUGL-UHFFFAOYSA-N
Pubchem ID :643953

Safety of Necrostatin 2 racemate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
human lung organoids 10 μM 24 or 48 hours Inhibition of RIPK1 activation, reduced SARS-CoV-2 viral load, and downregulated the expression of pro-inflaμMatory cytokines PMC8522117
mouse oligodendrocytes 1 μM 48 hours Inhibited necroptosis in oligodendrocytes, reduced the population of TUNEL+ cells, and increased the population of MBP+ cells. PMC8787401
primary human monocytes 70 μM 24 hours To evaluate the effect of Nec-1s on the death of Mtb-infected monocytes, results showed that Nec-1s treatment did not significantly alter the extent of cell death. PMC5943269
MEFs 1 μM 30 minutes To evaluate the effect of PERK inhibitors on TNF-mediated RIPK1 kinase-dependent cell death, GSK2656157 completely inhibited RIPK1 kinase-dependent cell death PMC5442476
L929 cells 1 μM 30 minutes To evaluate the effect of PERK inhibitors on TNF-mediated RIPK1 kinase-dependent cell death, GSK2656157 completely inhibited RIPK1 kinase-dependent necroptosis PMC5442476
FADD-deficient Jurkat cells 10 μM 30 minutes Evaluate the inhibitory effect of Nec-34 on TNFα-induced necroptosis PMC8169668
L929 cells 10 μM 30 minutes Evaluate the inhibitory effect of Nec-34 on TNFα-induced necroptosis PMC8169668
bEnd3 cells 20 μM 6 h OGD followed by reoxygenation for 24 h To investigate the role of MIF in inducing cell death through RIPK1 activation under OGD condition, results showed that Nec-1s could inhibit RIPK1 activation and cell death. PMC9945963

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
AC70 transgenic mice SARS-CoV-2 infection model intragastric administration 100 mg/kg twice a week for 4 weeks Nec-1s treatment reduced mortality, lung viral load, and CNS manifestation in SARS-CoV-2-infected AC70 transgenic mice PMC8522117
mice Olig1cre/+;Ninj2fl/fl mice intraperitoneal injection 50 mg/kg every 12 hours for 4 days Restored oligodendrocyte development and myelination, improved neuronal structure and activity, and alleviated depressive-like behaviors. PMC8787401
humanized mice humanized mouse model intraperitoneal injection 25 mg/kg Once daily for 28 days To evaluate the effect of Nec-1s on Mtb infection in humanized mice, results showed that Nec-1s treatment did not impact disease progression. PMC5943269
mice TNF-induced lethal shock model intravenous injection 100 mg/kg once daily for 28 days To evaluate the protective effect of GSK2656157 on TNF-induced lethal shock, GSK2656157 significantly improved the survival rate of mice PMC5442476
C57BL/6J male mice TNFα-induced systemic inflammatory response syndrome (SIRS) model Intragastric administration 100 mg/kg Once daily for 2 weeks Evaluate the protective effect of Nec-1s and (R)-484 on TNFα-induced SIRS PMC8169668
Mice SAMP8 mice Intraperitoneal injection 0.9 mg/kg single dose, monitored for 4 days Nec-1s significantly alleviated behavioral inflexibility and neuronal necroptosis in the BLA of SAMP8 mice PMC9284973
mice PIS model (perioperative ischemic stroke model) 2 mg/kg Single dose, observed for 18 hours To investigate the protective effects of Nec-1s on BBB disruption and neurological deficits in the PIS model, results showed that Nec-1s could reduce BBB disruption and neurological deficits. PMC9945963
mice APP/PS1 transgenic mouse model drinking water 10 mg/kg Started one week before, continued during behavior training and testing inhibition of RIPK1 reduced amyloid burden, levels of inflammatory cytokines, and improved memory deficits in APP/PS1 mice PMC5642727
mice folic acid-induced AKI model intraperitoneal injection 20 mg/kg Every 12 hours for 3 weeks Nec-1 reduced renal injury and cell death at 96 hours, indicating its protective role in late-stage AKI PMC5910825

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.60mL

0.72mL

0.36mL

18.00mL

3.60mL

1.80mL

36.01mL

7.20mL

3.60mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories